A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination with Sitagliptin in Subjects with Type with Type 2 Diabetes

StatusFinished
Effective start/end date26/09/1328/02/19

Funding

  • Takeda Global Research and Dev Ctr: $2,000.00

Keywords

  • Biotechnology & Drug Development, Diabetes, Obesity, & Metabolic Syndrome